STOCK TITAN

Cryoport director Hancock sells 74,379 shares

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
4

Rhea-AI Filing Summary

Daniel M. Hancock, a director of Cryoport, Inc. (CYRX), exercised options for 74,379 common shares on November 9, 2026, at exercise prices of $9.73, $12.65 and $7.00 per share. He also sold 74,379 shares at a weighted average of $20.207 per share. The transactions occurred automatically pursuant to a trading plan adopted May 27, 2026.

Insider HANCOCK DANIEL M
Role Director
Sold 74,379 shs ($1.50M)
Approx. gross sale proceeds $1.50M
Approx. exercise cost $737K
Approx. pre-tax spread $766K
Type Security Shares Price Value
Exercise Stock Option (right to buy) F1, F3 30,000 $0.00 $0.00
Exercise Stock Option (right to buy) F1, F4 23,830 $0.00 $0.00
Exercise Stock Option (right to buy) F1, F5 20,549 $0.00 $0.00
Exercise Common Stock F1 30,000 $9.73 $292K
Exercise Common Stock F1 23,830 $12.65 $301K
Exercise Common Stock F1 20,549 $7.00 $144K
Sale Common Stock F1, F2 74,379 $20.207 $1.50M
Holdings After Transaction: Stock Option (right to buy) — 20,549 options (Direct); Common Stock — 69,052 shares (Direct)
Footnotes (5)
  1. F1. This transaction occurred automatically pursuant to a trading plan adopted by the reporting person on May 27, 2026.
  2. F2. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.47, inclusive.
  3. F3. 1/36 of the options vested on the 4th of each month for thirty-six months beginning on 1/4/2019.
  4. F4. 1/12 of the options vested on the 17th of the month for twelve months beginning 6/17/2024.
  5. F5. 1/12 of the options vested on the 6th of the month for twelve months beginning 7/6/2025.
Shares sold 74,379 shares November 9, 2026
Weighted average sale price $20.207 per share Sale on November 9, 2026
Options exercised 30,000 options Exercise price $9.73 per share on November 9, 2026
Option exercise price $9.73 per share For 30,000 options exercised on November 9, 2026
Options exercised 23,830 options Exercise price $12.65 per share on November 9, 2026
Option exercise price $12.65 per share For 23,830 options exercised on November 9, 2026
Options exercised 20,549 options Exercise price $7.00 per share on November 9, 2026
Option exercise price $7.00 per share For 20,549 options exercised on November 9, 2026
weighted average price financial
"The price reported is a weighted average price."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
trading plan financial
"automatically pursuant to a trading plan adopted by the reporting person"
A trading plan is a written set of rules an investor follows about what to buy or sell, when to enter and exit positions, and how much risk to accept—like a travel itinerary that maps the route, stops, and budget before a trip. It matters because it helps remove emotional decisions during market swings, enforces discipline, and makes performance easier to review and improve, reducing the chance of costly impulsive moves.
vested financial
"1/36 of the options vested on the 4th of each month"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many CYRX shares did Daniel M. Hancock sell, and at what price?

Daniel M. Hancock sold 74,379 CYRX shares on November 9, 2026, at a weighted average of $20.207 per share. The sale executions ranged from $20.00 to $20.47 per share and occurred automatically pursuant to a trading plan adopted May 27, 2026.

What were Daniel M. Hancock’s CYRX option exercise prices?

He exercised options for 30,000 shares at $9.73 per share, 23,830 shares at $12.65 per share, and 20,549 shares at $7.00 per share on November 9, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
HANCOCK DANIEL M

(Last)(First)(Middle)
C/O CRYOPORT INC.
112 WESTWOOD PLACE, SUITE 350

(Street)
BRENTWOOD TENNESSEE 37027

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Cryoport, Inc. [ CYRX ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
11/09/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock11/09/2026M30,000(1)A$9.7399,052D
Common Stock11/09/2026M23,830(1)A$12.65122,882D
Common Stock11/09/2026M20,549(1)A$7143,431D
Common Stock11/09/2026S74,379(1)D$20.207(2)69,052D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (right to buy)$9.7311/09/2026M30,000(1) (3)01/04/2029Common Stock30,000$0.000D
Stock Option (right to buy)$12.6511/09/2026M23,830(1) (4)05/17/2031Common Stock23,830$0.000D
Stock Option (right to buy)$711/09/2026M20,549(1) (5)06/06/2032Common Stock20,549$0.0020,549D
Explanation of Responses:
1. This transaction occurred automatically pursuant to a trading plan adopted by the reporting person on May 27, 2026.
2. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.47, inclusive.
3. 1/36 of the options vested on the 4th of each month for thirty-six months beginning on 1/4/2019.
4. 1/12 of the options vested on the 17th of the month for twelve months beginning 6/17/2024.
5. 1/12 of the options vested on the 6th of the month for twelve months beginning 7/6/2025.
Remarks:
With respect to prices reported as weighted average prices in Table I, the reporting person undertakes to provide to Cryoport, Inc., any security holder of Cryoport, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in the applicable footnotes to this Form 4.
/s/ Daniel M. Hancock11/12/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Keep reading